V Diehl, J Franklin, D Hasenclever, H Tesch, M Pfreundschuh, B Lathan, U Paulus, M Sieber, J U Rüffer, M Sextro, A Engert, J Wolf, R Hermann, L Holmer, U Stappert-Jahn, E Winnerlein-Trump, G Wulf, S Krause, A Glunz, K von Kalle, H Bischoff, C Haedicke, E Dühmke, A Georgii, M Loeffler
The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological growth factor support, the dosages of cyclophosphamide, etoposide and adriamycin could be moderately escalated. The 3-armed multicentre HD9 trial (recruitment 1993-1998; 1300 patients randomised) aimed to compare BEACOPP with the standard COPP/ABVD chemotherapy and to detect and measure the gain in efficacy, if any, due to moderate dose escalation of BEACOPP...
1998: Annals of Oncology: Official Journal of the European Society for Medical Oncology